Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Site Directed Mutagenesis. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN119899823A reveals a novel lipase mutant enabling mild, cost-effective production of chiral pharmaceutical intermediates with superior stereoselectivity.
Patent CN115058406A reveals a novel esterase mutant for cosolvent-free l-menthol production. This breakthrough offers significant cost reduction and supply chain reliability for fine chemical manufacturers.
Patent CN109456952B reveals a novel omega-transaminase mutant for Sitafloxacin intermediates. Discover cost-effective, scalable biocatalytic solutions for high-purity chiral amine production.
Patent CN101407780B details a novel site-directed mutagenesis method for producing high-purity (R)-phenylethylene glycol, offering significant cost and supply chain advantages.
Patent CN116334022B reveals high-efficiency transaminase mutant for Rivastigmine intermediate. Offers superior yield and purity for scalable pharmaceutical manufacturing.
Patent CN107201355B details a novel phenylalanine deaminase mutant enabling cost-effective, high-purity D-phenylalanine production via single-step enzymatic catalysis.
Novel KmAKR mutants enable high-yield enzymatic synthesis of rosuvastatin side chains, offering superior stability and cost-effective manufacturing solutions.
Patent CN111411095B discloses a novel recombinant (R)-ω-transaminase mutant with high activity and stereoselectivity for efficient sitagliptin intermediate production, ensuring supply chain stability.
Patent CN112680425B reveals a novel alcohol dehydrogenase mutant for producing high-purity (S)-CHBE. This biocatalytic route offers significant cost reduction and supply chain reliability for statin manufacturing.
Patent CN109929822A reveals enhanced lipase mutants for resolving chiral esters. This breakthrough offers significant cost reduction and supply chain reliability for agrochemical intermediate manufacturing.
Patent CN108118035B reveals high-concentration enzymatic route reducing costs and improving purity for global supply chains.
Patent CN111154746B reveals high-activity amidase mutants enabling green, scalable production of 2-chloronicotinic acid for agrochemical and pharmaceutical applications.
Patent CN111235123A reveals a novel carbonyl reductase enabling high-substrate loading biocatalysis, offering significant cost reduction and purity advantages for pharmaceutical manufacturing.
Patent CN110577941A reveals mutated amine dehydrogenase for asymmetric reductive amination. Enables cost reduction in pharmaceutical intermediates manufacturing with high optical purity.
Patent CN117660389A reveals mutant transaminase for chiral amines. Offers high conversion and purity for pharma and agrochemical manufacturing supply chains.
Patent CN111411094B discloses a novel mutant enzyme achieving 95.4% conversion at high substrate concentrations, offering significant cost reduction in API manufacturing.
Patent CN103013945B details a novel epoxide hydrolase mutant enhancing hydrolytic activity and enantioselectivity for beta-blocker synthesis, offering significant cost and supply chain advantages.
Patent CN113444712B reveals novel L-aspartate-alpha-decarboxylase mutants boosting beta-alanine yields. Discover cost-effective biocatalysis solutions for pharma intermediates.
Novel S173Q/Q360Y mutant enzyme boosts D-alanine yield by 20% and stability 3-fold, offering cost-effective pharma intermediate solutions.
Patent CN117402920A details a novel ketoreductase mutant for asymmetric reduction. This report analyzes cost reduction in chiral drug manufacturing and supply chain reliability for global buyers.